Apogenix Starts Phase I With its Lead Compound AGP101
Heidelberg, October 07, 2008 - Apogenix GmbH, a biopharmaceutical company developing novel drugs based on the targeted modulation of apoptosis (programmed cell death), today announced that the Company has started the clinical Phase I trial in healthy volunteers with its lead compound AGP101... more
Apogenix Raises EUR 27.5m in Series B Financing Round
Heidelberg, April 30, 2008 - Apogenix GmbH, a biopharmaceutical company developing novel drugs based on the targeted modulation of apoptosis (programmed cell death), today announced the closing of its second financing round. The financing round totals EUR 27.5m (approx. USD 44m) and will be dedicated to the development of Apogenix´ research and development programs for novel therapeutics to treat diseases such as "acute Graft-versus-Host Disease" and cancer. .... more
Heidelberg, October 07, 2008 - Apogenix GmbH, a biopharmaceutical company developing novel drugs based on the targeted modulation of apoptosis (programmed cell death), today announced that the Company has started the clinical Phase I trial in healthy volunteers with its lead compound AGP101... more
Two Grants Totaling EUR 1.65 million by the German Federal Ministry of Education and Research (BMBF) to Support Apogenix' Research
German Cancer Research Center (DKFZ) exercises option to invest EUR 0.5 Million as part of recent Series B financing round
Heidelberg, September 19, 2008 – Apogenix GmbH, a biopharmaceutical company developing novel protein therapeutics based on the targeted modulation of apoptosis (Programmed cell death), today announced the publication of new research findings of its scientific advisor, Dr Ana Martin-Villalba, in this month's Cancer Cell (March 2008).... more
Heidelberg, April 30, 2008 - Apogenix GmbH, a biopharmaceutical company developing novel drugs based on the targeted modulation of apoptosis (programmed cell death), today announced the closing of its second financing round. The financing round totals EUR 27.5m (approx. USD 44m) and will be dedicated to the development of Apogenix´ research and development programs for novel therapeutics to treat diseases such as "acute Graft-versus-Host Disease" and cancer. .... more